New eye drop targets Mite-Related eyelid inflammation in phase 2 trial
Disease control
Ongoing
This study tests a new eye drop (APT-001, containing spinosad 1.8%) for blepharitis, a condition causing red, irritated eyelids often linked to tiny mites. About 100 people with symptoms will receive either the active drop or a placebo. The goal is to see if the treatment clears …
Phase: PHASE2 • Sponsor: Aperta Biosciences, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC